Maria Mora Pinzon, MD, MS, FACPM, was recently appointed to assistant professor on the tenure track in the Division of Geriatrics and Gerontology at the University of Wisconsin School of Medicine and Public Health, where she will continue working with the Wisconsin Alzheimer’s Institute and expand her research program.
IEA News
Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval
On the latest episode of the podcast, Dementia Matters, host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials.
Dr. Nathaniel Chin discusses the FDA approval of Leqembi on WPR
Nathaniel Chin, MD, joined host Rob Ferrett on the call-in program “Central Time” on The Ideas Network of Wisconsin Public Radio. Chin discussed the recent FDA approval of the drug Leqembi (lecanemab) to help with early Alzheimer’s and answered callers’ questions.
Dr. Cynthia Carlsson discusses the FDA approval of Leqembi
Cynthia Carlsson, MD, MS, was recently interviewed by CBS 58 News in Milwaukee about the U.S. Food and Drug Administration (FDA)
approval of Leqembi (lecanemab), which showed a reduction of clinical decline in a study of people with early Alzheimer’s disease.
FDA approves Alzheimer’s disease drug lecanemab
On January 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.
Dr. Sanjay Asthana appointed to serve on the National Advisory Council on Aging
Sanjay Asthana, MD, is the founding director of the Wisconsin Alzheimer’s Disease Research Center (ADRC) and an internationally renowned researcher and leader in the field of Alzheimer’s disease. The US Secretary of Health and Human …
Dr. Ozioma Okonkwo appointed to NIA-AA Alzheimer’s workgroup
Ozioma Okonkwo, PhD, has been appointed to participate in a National Institute on Aging (NIA) Alzheimer’s and Alzheimer’s Association workgroup, establishing the definition and classification of Alzheimer’s disease.
Dr. Sterling Johnson awarded Vilas Distinguished Achievement Professorship
Sterling Johnson, PhD, has been awarded a Vilas Distinguished Achievement Professorship, an appointment given to extraordinary members of the University of Wisconsin–Madison faculty. The award provides five years of flexible funding and recognizes distinguished scholarship and standout teaching and service efforts.
Companies announce findings about potential new Alzheimer’s drug lecanemab
Dr. Cynthia Carlsson, MD, MS spoke to multiple media outlets about the news, sharing information about a current UW study investigating use of lecanemab.
Meeting new friends and shaping future medical professionals
Each school year, Wisconsin Alzheimer’s Institute hosts New Friends, a unique program bringing together people living with memory loss and UW–Madison students interested in a career in healthcare. New Friends gives people living with memory impairment an opportunity to express their hopes regarding their health care and to participate in the training of future health care providers.